Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2020

Open Access 01-05-2020 | Original Article

In vivo three-dimensional evaluation of tumour hypoxia in nasopharyngeal carcinomas using FMT-CT and MSOT

Authors: Wenhui Huang, Kun Wang, Yu An, Hui Meng, Yuan Gao, Zhiyuan Xiong, Hao Yan, Qian Wang, Xuekang Cai, Xin Yang, Bin Zhang, Qiuying Chen, Xing Yang, Jie Tian, Shuixing Zhang

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2020

Login to get access

Abstract

Purpose

Accurate evaluation of hypoxia is particularly important in patients with nasopharyngeal carcinoma (NPC) undergoing radiotherapy. The aim of this study was to propose a novel imaging strategy for quantitative three-dimensional (3D) evaluation of hypoxia in a small animal model of NPC.

Methods

A carbonic anhydrase IX (CAIX)-specific molecular probe (CAIX-800) was developed for imaging of hypoxia. Mouse models of subcutaneous, orthotopic, and spontaneous lymph node metastasis from NPC (5 mice per group) were established to assess the imaging strategy. A multi-modality imaging method that consisted of a hybrid combination of fluorescence molecular tomography-computed tomography (FMT-CT) and multispectral optoacoustic tomography (MSOT) was used for 3D quantitative evaluation of tumour hypoxia. Magnetic resonance imaging, histological examination, and immunohistochemical analysis were used as references for comparison and validation.

Results

In the early stage of NPC (2 weeks after implantation), FMT-CT enabled precise 3D localisation of the hypoxia biomarker with high sensitivity. At the advanced stage (6 weeks after implantation), MSOT allowed multispectral analysis of the biomarker and haemoglobin molecules with high resolution. The combination of high sensitivity and high resolution from FMT-CT and MSOT could not only detect hypoxia in small-sized NPCs but also visualise the heterogeneity of hypoxia in 3D.

Conclusions

Integration of FMT-CT and MSOT could allow comprehensive and quantifiable evaluation of hypoxia in NPC. These findings may potentially benefit patients with NPC undergoing radiotherapy in the future.
Appendix
Available only for authorised users
Literature
1.
2.
Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9:674–87.CrossRefPubMed
3.
4.
Hui EP, Chan ATC, Pezzella F, Turley H, To KF, Poon TCW, et al. Coexpression of hypoxia-inducible factors 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002;8:2595–604.PubMed
5.
Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 2006;24:727–35.CrossRefPubMed
6.
Chen Y, Li X, Wu S, Xu G, Zhou Y, Gong L, et al. Expression of HIF-1alpha and CAIX in nasopharyngeal carcinoma and their correlation with patients' prognosis. Med Oncol. 2014;31:304.CrossRefPubMedPubMedCentral
7.
8.
9.
Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225–39.CrossRefPubMed
10.
Dewhirst MW, Birer SR. Oxygen-enhanced MRI is a major advance in tumour hypoxia imaging. Cancer Res. 2016;76:769–72.CrossRefPubMed
11.
Liu JN, Bu W, Shi J. Chemical design and synthesis of functionalized probes for imaging and treating tumour hypoxia. Chem Rev. 2017;117:6160–224.CrossRefPubMed
12.
Zegers CM, Hoebers FJ, van Elmpt W, Bons JA, Ollers MC, Troost EG, et al. Evaluation of tumour hypoxia during radiotherapy using [(18)F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2016;43:2139–46.CrossRefPubMedPubMedCentral
13.
Zegers CM, van Elmpt W, Reymen B, Even AJ, Troost EG, Ollers MC, et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumours using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Cancer Res. 2014;20:6389–97.CrossRefPubMedPubMedCentral
14.
Bekaert L, Valable S, Lechapt-Zalcman E, Ponte K, Collet S, Constans JM, et al. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging. 2017;44:1383–92.CrossRefPubMed
15.
Dubois LJ, Lambin P. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A. 2011;108:14620–5.CrossRefPubMedPubMedCentral
16.
Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun. 2012;3:783.CrossRefPubMed
17.
Ale A, Ermolayev V, Herzog E, Cohrs C, de Angelis MH, Ntziachristos V. FMT-XCT: in vivo animal studies with hybrid fluorescence molecular tomography-X-ray computed tomography. Nat Methods. 2012;9:615–20.CrossRefPubMed
18.
Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol. 2005;23:313–20.CrossRefPubMed
19.
An Y, Liu J, Zhang G, Jiang S, Ye J, Chi C, et al. Compactly supported radial basis function-based meshless method for photon propagation model of fluorescence molecular tomography. IEEE Trans Med Imaging. 2017;36:366–73.CrossRefPubMed
20.
Berninger MT, Mohajerani P, Kimm M, Masius S, Ma X, Wildgruber M, et al. Fluorescence molecular tomography of DiR-labeled mesenchymal stem cell implants for osteochondral defect repair in rabbit knees. Eur Radiol. 2017;27:1105–13.CrossRefPubMed
21.
Taruttis A, Ntziachristos V. Advances in real-time multispectral optoacoustic imaging and its applications. Nat Photonics. 2015;9:219–27.CrossRef
22.
Razansky D, Buehler A, Ntziachristos V. Volumetric real-time multispectral optoacoustic tomography of biomarkers. Nat Protoc. 2011;6:1121–9.CrossRefPubMed
23.
Li ML, Oh JT, Xie X, Geng K, Wang W, Li C, et al. Simultaneous molecular and hypoxia imaging of brain tumours in vivo using spectroscopic photoacoustic tomography. Proc IEEE. 2008;96:481–9.CrossRef
24.
Wu D, Potluri N, Lu J, Kim Y, Rastinejad F. Structural integration in hypoxia-inducible factors. Nature. 2015;524:303–8.CrossRefPubMed
25.
Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumour-associated carbonic anhydrases. Cancer Res. 2000;60:7075–83.PubMed
26.
Hoogsteen IJ, Marres HA, Wijffels KI, Rijken PF, Peters JP, van den Hoogen FJ, et al. Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res. 2005;11:97–106.PubMed
27.
Beasley N, Wykoff C, Watson P, Leek R, Turley H, Gatter K, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001;61:5262–7.PubMed
28.
Wichert M, Krall N, Decurtins W, Franzini RM, Pretto F, Schneider P, et al. Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation. Nat Chem. 2015;7:241–9.CrossRefPubMed
29.
Yang X, Minn I, Rowe SP, Banerjee SR, Gorin MA, Brummet M, et al. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. Oncotarget. 2015;6:33733–42.PubMedPubMedCentral
30.
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.CrossRefPubMed
31.
Hong B, Lui VWY, Hashiguchi M, Hui EP, Chan ATC. Targeting tumor hypoxia in nasopharyngeal carcinoma. Head Neck-J Sci Spec Head Neck. 2013;35:133–45.CrossRef
32.
Sung FL, Hui EP, Tao Q, Li H, Tsui NB, Lo YM, et al. Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett. 2007;253:74–88.CrossRefPubMed
33.
Liu T, Ding Y, Xie W, Li Z, Bai X, Li X, et al. An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer Res. 2007;13:3960–7.CrossRefPubMed
34.
Cairns RA, Hill RP. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res. 2004;64:2054–61.CrossRefPubMed
35.
36.
An Y, Liu J, Zhang G, Ye J, Du Y, Mao Y, et al. A novel region reconstruction method for fluorescence molecular tomography. IEEE Trans Biomed Eng. 2015;62:1818–26.CrossRefPubMed
37.
38.
Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiol. 2001;11:1968–74.CrossRefPubMed
39.
40.
Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, et al. PET of hypoxia with 89Zr-labeled cG250-F(ab′)2 in head and neck tumours. J Nucl Med. 2010;51:1076–83.CrossRefPubMed
41.
Lawrentschuk N, Lee FT, Jones G, Rigopoulos A, Mountain A, O'Keefe G, et al. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT. Urol Oncol. 2011;29:411–20.CrossRefPubMed
42.
Gremse F, Theek B, Kunjachan S, Lederle W, Pardo A, Barth S, et al. Absorption reconstruction improves biodistribution assessment of fluorescent nanoprobes using hybrid fluorescence-mediated tomography. Theranostics. 2014;4:960–71.CrossRefPubMedPubMedCentral
43.
James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92:897–965.CrossRefPubMed
44.
Alexander D, Burton NC, Vasilis N. Multispectral optoacoustic tomography at 64, 128, and 256 channels. J Biomed Opt. 2014;19:36021.CrossRef
45.
Nagengast WB, Hartmans E, Garcia-Allende PB, Peters FTM, Linssen MD, Koch M, et al. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A. Gut. 2019;68:7–10.CrossRefPubMed
46.
Ansari R, Zhang EZ, Desjardins AE, Beard PC. All-optical forward-viewing photoacoustic probe for high-resolution 3D endoscopy. Light-Sci Appl. 2018;7:9.CrossRef
47.
Brita Singers SR, Jan A, Jens O, Horsman MR. Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. Radiother Oncol. 2007;83:362–6.CrossRef
Metadata
Title
In vivo three-dimensional evaluation of tumour hypoxia in nasopharyngeal carcinomas using FMT-CT and MSOT
Authors
Wenhui Huang
Kun Wang
Yu An
Hui Meng
Yuan Gao
Zhiyuan Xiong
Hao Yan
Qian Wang
Xuekang Cai
Xin Yang
Bin Zhang
Qiuying Chen
Xing Yang
Jie Tian
Shuixing Zhang
Publication date
01-05-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04526-x

Other articles of this Issue 5/2020

European Journal of Nuclear Medicine and Molecular Imaging 5/2020 Go to the issue

Original Article

[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer

Original Article

Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy

Letter to the Editor

“Luke! Luke! Don’t! It’s a trap!”—spotlight on bias in animal experiments in nuclear oncology

Original Article

Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody

Original Article

18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients

Original Article

Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy